Jiangxi Synergy Pharmaceutical Co., Ltd. (SHE:300636)
China · Delayed Price · Currency is CNY 8.15
+0.07 (0.87%)
Feb 4, 2026, 3:04 PM CST
SHE:300636 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 824.24 | 757.93 | 720.7 | 718.59 | 589.07 | 433.97 |
Other Revenue | 0.96 | 0.96 | 1.43 | 1.32 | 3.06 | 1.45 |
| 825.2 | 758.89 | 722.14 | 719.91 | 592.13 | 435.42 | |
Revenue Growth (YoY) | 12.67% | 5.09% | 0.31% | 21.58% | 35.99% | 5.41% |
Cost of Revenue | 602.18 | 539.38 | 501.78 | 493.84 | 420.85 | 285.43 |
Gross Profit | 223.02 | 219.51 | 220.36 | 226.07 | 171.28 | 149.99 |
Selling, General & Admin | 65.08 | 63.78 | 59.85 | 51.33 | 39.01 | 31.02 |
Research & Development | 61.28 | 59.45 | 63.15 | 60.91 | 39.02 | 35.3 |
Other Operating Expenses | 8.66 | 5.35 | 3.62 | 2.39 | 1.82 | 1.5 |
Operating Expenses | 135.9 | 129.84 | 126.51 | 116.11 | 81.96 | 65.2 |
Operating Income | 87.12 | 89.67 | 93.85 | 109.95 | 89.32 | 84.79 |
Interest Expense | -14.51 | -18.14 | -9.9 | -7.7 | -5.69 | -8.99 |
Interest & Investment Income | 27.03 | 30.8 | 17.58 | 2.89 | 1.97 | 0.64 |
Currency Exchange Gain (Loss) | 5.84 | 5.84 | 3.03 | -2.13 | 0.85 | -1.31 |
Other Non Operating Income (Expenses) | -0.75 | -0.99 | -0.75 | -0.75 | -0.42 | -0.34 |
EBT Excluding Unusual Items | 104.74 | 107.17 | 103.81 | 102.27 | 86.02 | 74.79 |
Gain (Loss) on Sale of Investments | -0.66 | 0.05 | - | -1.21 | 0.26 | - |
Gain (Loss) on Sale of Assets | -0.66 | -1.17 | -1.32 | -0.18 | -1.01 | -1.73 |
Other Unusual Items | 17.46 | 8.64 | 10.01 | 5.27 | 3.07 | 5 |
Pretax Income | 101.61 | 114.69 | 112.5 | 106.15 | 88.34 | 78.06 |
Income Tax Expense | 7.1 | 8.11 | 6.52 | 5.48 | 7.22 | 8.01 |
Net Income | 94.51 | 106.58 | 105.98 | 100.67 | 81.12 | 70.05 |
Net Income to Common | 94.51 | 106.58 | 105.98 | 100.67 | 81.12 | 70.05 |
Net Income Growth | -23.20% | 0.57% | 5.28% | 24.10% | 15.80% | 45.01% |
Shares Outstanding (Basic) | 420 | 420 | 380 | 326 | 309 | 309 |
Shares Outstanding (Diluted) | 420 | 420 | 380 | 346 | 338 | 310 |
Shares Change (YoY) | -0.01% | 10.39% | 9.89% | 2.55% | 9.05% | -0.43% |
EPS (Basic) | 0.23 | 0.25 | 0.28 | 0.31 | 0.26 | 0.23 |
EPS (Diluted) | 0.23 | 0.25 | 0.28 | 0.29 | 0.24 | 0.23 |
EPS Growth | -23.20% | -8.90% | -4.20% | 21.02% | 6.19% | 45.62% |
Free Cash Flow | -24.6 | 148.7 | -50.9 | -115.5 | -293.33 | -149.93 |
Free Cash Flow Per Share | -0.06 | 0.35 | -0.13 | -0.33 | -0.87 | -0.48 |
Dividend Per Share | 0.040 | 0.040 | 0.040 | 0.045 | 0.040 | 0.035 |
Dividend Growth | - | - | -11.11% | 12.50% | 12.99% | 0.57% |
Gross Margin | 27.03% | 28.93% | 30.51% | 31.40% | 28.93% | 34.45% |
Operating Margin | 10.56% | 11.82% | 13.00% | 15.27% | 15.09% | 19.47% |
Profit Margin | 11.45% | 14.04% | 14.68% | 13.98% | 13.70% | 16.09% |
Free Cash Flow Margin | -2.98% | 19.59% | -7.05% | -16.04% | -49.54% | -34.43% |
EBITDA | 234.74 | 203.4 | 162.39 | 175.99 | 140.34 | 137.12 |
EBITDA Margin | 28.45% | 26.80% | 22.49% | 24.45% | 23.70% | 31.49% |
D&A For EBITDA | 147.62 | 113.73 | 68.55 | 66.04 | 51.02 | 52.33 |
EBIT | 87.12 | 89.67 | 93.85 | 109.95 | 89.32 | 84.79 |
EBIT Margin | 10.56% | 11.82% | 13.00% | 15.27% | 15.09% | 19.47% |
Effective Tax Rate | 6.98% | 7.07% | 5.79% | 5.17% | 8.17% | 10.26% |
Revenue as Reported | 825.2 | 758.89 | 722.14 | 719.91 | 592.13 | 435.42 |
Advertising Expenses | - | 3.08 | 2.35 | 0.19 | 0.62 | 1.09 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.